Lectus Therapeutics appoints new chairman
This article was originally published in Scrip
Executive Summary
The chairman and CEO of Ablynx, Dr Edwin Moses, has been appointed non-executive chairman of the UK drug discovery and development company Lectus Therapeutics. Professor Raymond Hill, who was, until April 2008, executive director of licensing and external research (Europe) for Merck, Sharp & Dohme Research Laboratories, has been named non-executive director. Lectus has also appointed Dr Chas Bountra chairman of, and Professor Annette Dolphin to, its scientific advisory board (SAB). Mr Bountra succeeds Professor Leslie Iversen, who has chaired the SAB since its first meeting in 2003.